secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rein Therapeutics, Inc. (RNTX)
CIK:        0001420565
Form:       8-K
Filed at:   2026-02-19T23:59:59+00:00
Accession:  0001193125-26-059545
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Director Manuel C. Alves Aivado resigns from Rein Therapeutics board effective Feb 16
--------------------------------------------------------------------------------

- Manuel C. Alves Aivado, M.D., Ph.D., resigned as board member effective February 16, 2026.
- Resignation was not the result of any disagreement with the company's operations, policies, or practices.
- No replacement has been announced; board size and composition subsequent to departure not disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420565/000119312526059545/0001193125-26-059545-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420565/000119312526059545/d31606d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-059545

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer